Matthew E. McGuiness, MD | Authors

Cardiovascular Toxicity of Newer Chemotherapeutic Agents: The Heart of the Matter

June 15, 2014

Standard heart failure regimens remain the mainstay of therapy for chemotherapy-related cardiac dysfunction until newer randomized trials suggest otherwise, and earlier detection of toxicity through judicious surveillance with biomarkers and noninvasive imaging remains the cornerstone of management for the foreseeable future.